LLLennart Langenhoff

Lennart Langenhoff

*This is an algorithmically generated author record based on publicly available information.

Lennart Langenhoff has a total of 24 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    An Immuno-Infrared Sensor Detects Preclinical Alzheimer’s and Parkinson’s Disease by Protein Misfolding

    by Grischa Gerwert, Marvin Mann, Lennart Langenhoff, Nathalie Woitzik, Diana Hubert, Deniz Duman, Adrian Höveler, Sandy Budde, Jonas Simon, Léon Beyer, et al.

    The immuno-infrared sensor (iRS) detects misfolding of biomarker proteins in blood and provides thereby a very early and easily accessible diagnosis of Alzheimer’s and Parkinson’s disease. Only in early stages recently approved therapeutic Alzheimer′s drugs work efficiently. In symptom-free stages, lifestyle change can largely delay the disease progression, and the drugs may even block the disease progression. Population screening by a simple blood test will therefore be a game changer in the fight against neurodegenerative diseases. This was made possible by the new iRS platform. In the iRS platform, antibodies as catcher molecules concentrate the target protein biomarker on the functionalized attenuated total reflection crystal surface. A blocking layer prevents unspecific binding. A quantum cascade laser is used to measure the amide I absorbance maximum as a readout, indicating the degree of the biomarker misfolding and thereby disease progression.


  • Open Access

    MISFOLDING OF ALPHA-SYNUCLEIN AS BLOOD-BASED BIOMARKER FOR PARKINSON’S DISEASE

    by Lennart Langenhoff, Jonas Simon, Sandrina Weber, Diana Hubert, Martin Schuler, Marvin Mann, Vuk Puzovic, Grischa Gerwert, Adrian Hoeveler, Léon Beyer, et al.

    Parkinson’s disease (PD), dementia with Lewy bodies (DLB) and multiple system atrophy (MSA) are characterized by pathological aggregation of misfolded alpha-synuclein (αSyn) in the central and peripheral nervous systems. Seed amplification assays (SAAs) can detect misfolded αSyn in cerebrospinal fluid (CSF), allowing a more precise biological classification of these diseases. Translating biomarker-based diagnostics to blood represents a crucial milestone to democratize access to molecular testing, as blood sampling is minimally invasive and widely scalable. However, current blood-based SAA approaches require extensive sample preprocessing, which introduces variability and has yielded inconsistent results. Here, we present the immuno-infrared-sensor (iRS) platform, which detects misfolded αSyn directly in blood serum without sample preprocessing and without amplification. The iRS measures the secondary-structure distribution of αSyn by distinguishing α-helical/random-coil monomers from β-sheet-rich oligomers and fibrils. This conformational distribution reflects disease-associated structural changes in blood and provides information beyond the binary readout of SAAs. In a combined cohort (n = 127) consisting of 74 individuals with synucleinopathies (PD, DLB, MSA and isolated rapid eye movement sleep behavior disorder (iRBD)) and 53 controls, the assay achieved a receiver operating characteristic area under the curve (ROC AUC) of 0.94 (95% confidence interval (CI), 0.88–0.99), with 88% sensitivity and 89% specificity in serum using a dual-threshold classification that categorized individuals as controls (no misfolding, green), at risk (low misfolding, yellow) or diseased (high misfolding, red). By extending the iRS platform from CSF to blood serum, this study demonstrates αSyn misfolding as a promising blood-based structural biomarker for synucleinopathies. The iRS assay provides a broadly applicable platform technology for more precise biological classification, disease monitoring and assessment of drug response for PD in peripheral blood.